World Pancreatic Cancer Day: highlighting the PDAC cohort of our Rosalind Study

World Pancreatic Cancer Day: highlighting the PDAC cohort of our Rosalind Study

Rosalind Study

The network

The science

Publication Date:

Pancreatic cancer remains one of the most challenging cancers to treat. Understanding why some patients survive for many years could open new avenues for research. Our Rosalind Study investigates the biological characteristics of long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC). By studying exceptional survivors, we aim to uncover the biological mechanisms that could lead to new therapeutic targets.

Led by Gustave Roussy and Dr. Julieta Rodriguez, the mPDAC cohort of our Rosalind Study continues to grow:

  • 675 exceptional survivors with biobanked samples and their matched controls

  • 121 participating centers across 40+ countries

Our research has already led to the identification of several therapeutic targets, bringing us closer to translating the biology of exceptional survivors into new therapeutic opportunities. More research updates are coming soon! This World Pancreatic Cancer Day, we reaffirm our commitment to learning from exceptional survivors, advancing cancer research and working alongside patients and their communities.


Updated: November 19, 2026

UNTIL ALL SURVIVE.

From frontline caregivers and patients to researchers and media voices, we bring diverse perspectives together to advance cancer research. Let’s talk.

UNTIL ALL SURVIVE.

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

©2024 Cure51, All Rights Reserved

©2026 Cure51, All Rights Reserved

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.